Patient Factors Influencing the Prescribing of Lipid Lowering Drugs for Primary Prevention of Cardiovascular Disease in UK General Practice: A National Retrospective Cohort Study

被引:46
|
作者
Wu, Jianhua [1 ]
Zhu, Shihua [2 ]
Yao, Guiqing Lily [3 ]
Mohammed, Mohammed A. [2 ]
Marshall, Tom [2 ]
机构
[1] Univ London, Ctr Environm & Prevent Med, Barts & London Sch Med & Dent, London, England
[2] Univ Birmingham, Sch Publ Hlth & Populat Sci, Birmingham, W Midlands, England
[3] Univ Southampton, Fac Med, Southampton SO9 5NH, Hants, England
来源
PLOS ONE | 2013年 / 8卷 / 07期
关键词
CORONARY-HEART-DISEASE; MULTIVARIATE PREDICTION; EUROPEAN GUIDELINES; HEALTH-CARE; CHOLESTEROL; RISK; HYPERCHOLESTEROLEMIA; UNDERTREATMENT; POPULATION; MANAGEMENT;
D O I
10.1371/journal.pone.0067611
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Guidelines indicate eligibility for lipid lowering drugs, but it is not known to what extent GPs' follow guidelines in routine clinical practice or whether additional clinical factors systematically influence their prescribing decisions. Methods: A retrospective cohort analysis was undertaken using electronic primary care records from 421 UK general practices. At baseline (May 2008) patients were aged 30 to 74 years, free from cardiovascular disease and not taking lipid lowering drugs. The outcome was prescription of a lipid lowering drug within the next two years. The proportions of eligible and ineligible patients prescribed lipid lowering drugs were reported and multivariable logistic regression models were used to investigate associations between age, sex, cardiovascular risk factors and prescribing. Results: Of 365,718 patients with complete data, 13.8% (50,558) were prescribed lipid lowering drugs: 28.5% (21,101/74,137) of those eligible and 10.1% (29,457/291,581) of those ineligible. Only 41.7% (21,101/50,558) of those prescribed lipid lowering drugs were eligible. In multivariable analysis prescribing was most strongly associated with increasing age (OR for age >= 65 years 4.21; 95% CI 4.05-4.39); diabetes (OR 4.49; 95% CI 4.35-4.64); total cholesterol level >= 7 mmol/L (OR 2.20; 95% CI 2.12-2.29); and >= 4 blood pressure measurements in the past year (OR 4.24; 95% CI 4.06-4.42). The predictors were similar in eligible and ineligible patients. Conclusions: Most lipid lowering drugs for primary prevention are prescribed to ineligible patients. There is underuse of lipid lowering drugs in eligible patients.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Use of lipid lowering therapy in primary care across Europe: results from the European study on cardiovascular risk prevention in daily practice (eurika)
    Halcox, J. P. J.
    Tubach, F.
    Banegas, J. R.
    Borghi, C.
    Dallongeville, J.
    De Backer, G.
    Perk, J.
    Steg, P. G.
    Rodriguez-Artalejo, F.
    Guallar, E.
    EUROPEAN HEART JOURNAL, 2012, 33 : 810 - 810
  • [32] Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: Cohort study using data from the UK General Practice Research Database
    Russmann, S
    Kaye, JA
    Jick, SS
    Jick, H
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 60 (01) : 76 - 82
  • [33] Do statins benefit low-risk population for primary prevention of atherosclerotic cardiovascular disease: A retrospective cohort study
    Ryou, In Sun
    Kim, Ju Young
    Park, Hwa Yeon
    Oh, Sohee
    Kim, Sehun
    Kim, Hwa Jung
    FRONTIERS IN MEDICINE, 2022, 9
  • [34] Aspirin as a Primary Prevention of Cardiovascular Disease in High-Risk New Diabetes Patients: A Retrospective Cohort Study in Taiwan
    Chiang, Chiawei
    Chen, Ta-Cheng
    Yeh, Yi-Chun
    Chen, Yen-Yu
    NEUROLOGY, 2019, 92 (15)
  • [35] Correction to: Knowledge of cardiovascular disease risk factors and practice of primary prevention of cardiovascular disease by Community Pharmacists in Nigeria: a cross-sectional study
    Casmir E. Amadi
    Folasade O. Lawal
    Amam C. Mbakwem
    Jayne N. Ajuluchukwu
    David A. Oke
    International Journal of Clinical Pharmacy, 2020, 42 : 293 - 293
  • [36] GOUT IS AN INDEPENDENT RISK FACTOR FOR ALL TYPES OF VASCULAR DISEASE: A RETROSPECTIVE COHORT STUDY IN THE UK GENERAL PRACTICE RESEARCH DATABASE
    Clarson, Lorna E.
    Hider, Samantha L.
    Belcher, John
    Heneghan, Carl
    Roddy, Edward
    Mallen, Christian D.
    RHEUMATOLOGY, 2013, 52 : 38 - 39
  • [37] High risk of cardiovascular disease in patients with type 1 diabetes in the UK - A cohort study using the General Practice Research Database
    Soedamah-Muthu, SS
    Fuller, JH
    Mulnier, HE
    Raleigh, VS
    Lawrenson, RA
    Colhoun, HM
    DIABETES CARE, 2006, 29 (04) : 798 - 804
  • [38] Optimal risk thresholds for prescribing statins as primary prevention of cardiovascular disease in Iranian general population: a benefit-harm modelling study
    Davood Khalili
    Hassan Saadati
    Hamid Reza Baradaran
    Farzad Hadaegh
    Ewout W. Steyerberg
    Mark Woodward
    Goodarz Danaei
    BMC Cardiovascular Disorders, 24 (1)
  • [39] How do the Australian guidelines for lipid-lowering drugs perform in practice? Cardiovascular disease risk in the AusDiab Study, 1999-2000
    Chen, Lei
    Rogers, Sophie L.
    Colagiuri, Stephen
    Cadilhac, Dominique A.
    Mathew, Timothy H.
    Boyden, Andrew N.
    Peeters, Anna
    Magliano, Dianna J.
    Shaw, Jonathan E.
    Zimmet, Paul Z.
    Tonkin, Andrew M.
    MEDICAL JOURNAL OF AUSTRALIA, 2008, 189 (06) : 319 - 322
  • [40] How do the Australian guidelines for lipid-lowering drugs perform in practice? Cardiovascular disease risk in the AusDiab Study, 1999-2000
    Neaverson, Michael A.
    MEDICAL JOURNAL OF AUSTRALIA, 2009, 190 (04) : 222 - 223